Comparative Pharmacology
Head-to-head clinical analysis: CONRAY 43 versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY 43 versus DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM.
CONRAY 43 vs DIATRIZOATE MEGLUMINE AND DIATRIZOATE SODIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, enhancing vascular and tissue contrast during imaging.
Radiopaque contrast agent that attenuates X-rays, providing visualization of vascular and urinary structures. It is a high-osmolality ionic dimer that distributes in extracellular fluid and is excreted renally.
Intravenous: 0.5-1.0 mL/kg (20-43 mg I/kg) for CT; intra-arterial: 5-15 mL for selective studies; maximum single dose 150 mL.
Intra-arterial or intravenous administration; adult dose varies by procedure: for intravenous urography, 50-100 mL of 60% solution; for CT enhancement, 100-150 mL of 60% solution; maximum total dose 4.2 g iodine/kg body weight.
None Documented
None Documented
2 hours (normal renal function); prolonged to 20-40 hours in severe renal impairment (CrCl <10 mL/min).
1-2 hours in normal renal function; prolonged in renal impairment (up to 20-30 hours in severe impairment)
Renal: >90% via glomerular filtration; unchanged drug. Biliary: <1%. Fecal: negligible.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: <5%
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent